Interventional or implantable medical instrument drug coating and preparation method thereof

Abstract

The invention relates to an interventional or implantable medical instrument drug coating and a preparation method thereof. The core of the interventional or implantable medical instrument drug coating is a grafted drug copolymer. The preparation method comprises the following steps: under the action of a catalyst, an active drug is covalently connected with a hydrophilic matrix to prepare the grafted drug copolymer, the grafted drug copolymer is dissolved and dispersed in a solvent, and then covered on the surface of an interventional or implantable medical instrument, and drying is performed. The covalent linkage manner can enhance the homogeneity of the drug and the matrix coating, improve the hydrophilicity and hydrophobicity balance of the drug and the adhesion-release balance of thedrug coating and the surface of the medical instrument, and enhance the efficiency that the drug is absorbed by tissues, penetrates through tissue stroma, and is taken in by cells. The homogeneity, uniformity and stability of the medical instrument drug coating are enhanced, the drug loading capacity is reduced, the drug loss is reduced, the drug entering blood circulation is reduced, and the absorption of the drug in target tissues and cells is increased, so that the toxicity is reduced, and the drug efficacy is improved.

Description

technical field [0001] The invention belongs to the field of medical devices, and in particular relates to a drug coating for intervention or implantation of medical devices and a preparation method thereof. Background technique [0002] Coronary atherosclerotic heart disease is a heart disease caused by atherosclerotic lesions in the coronary arteries, causing stenosis or blockage of the vessel lumen, resulting in myocardial ischemia, hypoxia or necrosis. It is often called "coronary heart disease". The main means of treating coronary heart disease is percutaneous coronary intervention (PCI), that is, to open the blocked lumen and achieve revascularization. [0003] In the 1970s, percutaneous transluminal coronary angioplasty (PTCA) was performed for the first time in human beings, creating a precedent for interventional treatment of coronary heart disease with simple balloon dilation of coronary artery stenosis. Although PTCA can immediately eliminate vascular stenosis, s...

AI Technical Summary

Problems solved by technology

The drug coating on the surface of the balloon prepared by this method is uneven, the particles are large, easy to fall off, and the drug is not easily absorbed by the tissue

[0010] The invention patent of authorized notification number CN103736154B uses organic acid salts and polyols to mix drugs to prepare drug-coated balloons, which also has the disadvantage of not being able to effectively promote the absorption of drugs by tissues and cells

[0011] It can be seen that the prior art basically requires modification or surface treatment of the balloon, and the coating process is complicated, which may easily cause uneven coating

The existing technologies all use water-soluble substrates, excipients, emulsifiers and / or plasticizers to mix with drugs or combine with weak forces such as hydrogen bonds to make drug coatings, but due to the polarity, molecular weight and solubility of each substance The difference in properties, such as poor coating homogeneity, easy to fall off to produce larger particles, unable to release drugs in a short time, and unable to efficiently absorb drugs by tissues and cells

Images